We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Inpeco

Inpeco is a global leader in automation systems for clinical laboratories and designs cutting-edge solutions for both... read more Featured Products: More products

Download Mobile App





Inpeco Launches Next-Generation Total Lab Automation System

By LabMedica International staff writers
Posted on 01 Aug 2024
Print article
Image: The new FlexLab X total lab automation system unveiled at ADLM 2024 (Photo courtesy of Inpeco)
Image: The new FlexLab X total lab automation system unveiled at ADLM 2024 (Photo courtesy of Inpeco)

At ADLM 2024, Inpeco SA (Novazzano, Switzerland) is introducing FlexLab X, its new total lab automation system, to the global laboratory medicine community.

Set to redefine automation excellence, FlexLab X offers enhanced flexibility, a best-in-class user experience, and excellent performance. Open and flexible by design, FlexLab X allows labs to freely combine analyzers from different vendors, for optimal patient outcomes. Its standardized track components enable space-saving layouts tailored to a lab’s needs that scale easily in three dimensions, to support future growth. Offering sleek graphical user interfaces (GUI) and powerful Data Analytics functionalities, FlexLab X is intuitively easy to use and monitor. This simplifies daily work and helps eliminate errors, while KPI dashboards provide actionable insights to streamline workflows.

Thanks to its outstanding performance, FlexLab X assures rapid and consistent turnaround times (TAT) at all sample volume levels, and it supports premium-quality results that are fully traceable. Moreover, FlexLab X is designed to maximize uptime and reduce running costs, contributing to an attractive return on investment (ROI). Clinical laboratories benefit from safe and efficient workflows that get the daily routine done. Premium-quality results support improved patient outcomes, and the attractive return delivered by a FlexLab X investment helps labs to better cope with increasing budget pressures.

Related Links:
Inpeco SA

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel

Spit Test More Accurate at Identifying Future Prostate Cancer Risk

Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based on a man's age, ethnicity, or if they are exhibiting symptoms. Since elevated PSA levels can indicate prostate cancer,... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.